+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liver Cancer Diagnostic Market Size, Share & Trends Analysis Report By Screening Type (Biopsy, Endoscopy, Laboratory Tests, Imaging), By Region (North America, APAC, Europe), And Segment Forecasts, 2019 - 2025

  • ID: 4751806
  • Report
  • January 2019
  • Region: North America, Europe, Asia Pacific
  • 111 pages
  • Grand View Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Hologic
  • Illumina,Inc.
  • Koninklijke Philips N.V.
  • Qiagen
  • Roche Diagnostics
  • MORE
The global liver cancer diagnostics market size is expected to reach USD 15.4 billion by 2025. The market is projected to expand at a CAGR of 8.1% over the estimated time period. Rise in disease incidence coupled with growing demand for novel diagnosis products are thrusting the growth of the market. Hepatocellular Carcinoma (HCC) is the most common type of primary liver cancer in adults. It is among the common causes of death in people with liver cirrhosis and the third-leading cause of cancer deaths across the globe. Poor survival rate and lack of therapies has made this disease a crucial health issue worldwide.

Government and some global health organizations are undertaking initiatives to raise awareness regarding liver cancer through various campaigns. These programs aim to create awareness about signs, symptoms, and complications associated with carcinomas. High costs associated with cancer treatments compared to other diseases have led to increasingly rigid treatment guidelines for expensive drugs and diagnostic tests across various markets. For instance, the Affordable Care Act, designed to improve quality of healthcare and reduce the cost associated with it. This act covers reimbursement for cancer diagnosis and treatment up to a certain extent. Governments in other countries are also taking efforts to overcome challenges, such as cost and access to cancer care.

Such efforts and insurance policies that cover cost of diagnosis and treatment of carcinomas are supporting market growth. Newer techniques developed for hepatocellular carcinoma render both liver transplant, as well as surgical resection, more effective and safer. Several etiological factors of HCC such as hepatitis infection and cirrhosis are modifiable and thus present a strong prospect to reduce disease mortality by preventive strategies. Key players and medical institutions are focusing on the development of advanced tests for HCC diagnosis. These factors along with high unmet needs are expected to propel the growth of liver cancer diagnostics market through the forecast period.

Further key findings from the study suggest:
  • Increasing awareness about liver cancer across the globe is expected to be the major factor driving the market growth
  • Laboratory tests emerged as the largest segment owing to increased demand for effective diagnostic tests for HCC
  • Oncofetal and Glucoprotein antigens accounted for the largest share in biomarkers segment
  • North America led the global liver cancer diagnostic market in 2017 and will maintain the dominance in future on account of rising awareness about early diagnosis and demand for novel diagnostic tests in the region
  • Illumina, Inc.; Qiagen; F. Hoffmann-La Roche Ltd.; Siemens Healthcare GmbH; and Thermo Fisher Scientific are some of the leading industry participants

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott Laboratories
  • Hologic
  • Illumina,Inc.
  • Koninklijke Philips N.V.
  • Qiagen
  • Roche Diagnostics
  • MORE
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.1.1 Information Procurement
1.2 Information or Data Analysis
1.3 Research Scope and Assumptions
1.4 List to Data Sources

Chapter 2 Executive Summary
2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation

Chapter 4 Industry Outlook
4.1 Market Variable Analysis
4.1.1 Failure rate of conventional diagnosis
4.1.2 Early detection leading to reduced healthcare costs
4.2 Market Restraint Analysis
4.2.1 High risk of radiation exposure and stringent regulatory guidelines
4.2.2 High cost and unmet needs

Chapter 5 Business Environment Analysis
5.1 SWOT Analysis; by factor (political & legal, economic and technological)
5.2 Porter’s five forces analysis

Chapter 6 Liver Cancer Diagnostics Market: Screening Type Business Analysis
6.1 Liver Cancer Diagnostics: Type Movement Analysis
6.2 Laboratory Tests
6.2.1 Laboratory Tests market estimates and forecast, 2014 - 2025
6.3 Biomarker Tests
6.3.1 Biomarker Tests market estimates and forecast, 2014 - 2025
6.3.1.1 Oncofetal And Glycoprotein Antigens
6.3.1.1.1 Oncofetal And Glycoprotein Market Estimates And Forecast, 2014 - 2025
6.3.1.2 Enzymes And Isoenzymes
6.3.1.2.1 Enzymes And Isoenzymes Market Estimates And Forecast, 2014 - 2025
6.3.1.3 Growth Factors And Receptors
6.3.1.3.1 Growth Factors And Receptors Market Estimates And Forecast, 2014 - 2025
6.3.1.4 Molecular Markers
6.3.1.4.1 Molecular Markers Market Estimates And Forecast, 2014 - 2025
6.3.1.5 Pathological Biomarkers
6.3.1.5.1 Pathological Biomarkers Market Estimates And Forecast, 2014 - 2025
6.3.2 Blood Tests
6.3.2.1 Blood Tests Market Estimates And Forecast, 2014 - 2025
6.4 Imaging
6.4.1 Imaging Market Estimates And Forecast, 2014 - 2025
6.5 Endoscopy
6.5.1 Endoscopy Market Estimates And Forecast, 2014 - 2025
6.6 Biopsy
6.6.1 Biopsy Market Estimates And Forecast, 2014 - 2025
6.7 Others
6.7.1 Others Market Estimates And Forecast, 2014 - 2025

Chapter 7 Liver Cancer Diagnostics Market Regional Business Analysis
7.1 Liver Cancer Diagnostics Market: Regional Movement Analysis
7.2 North America
7.2.1 North America market estimates and forecast, 2014 - 2025
7.2.2 U.S.
7.2.2.1 U.S. market estimates and forecast, 2014 - 2025
7.2.3 Canada
7.2.3.1 Canada market estimates and forecast, 2014 - 2025
7.3 Europe
7.3.1 Europe market estimates and forecast, 2014 - 2025
7.3.2 Germany
7.3.2.1 Germany market estimates and forecast, 2014 - 2025
7.3.3 U.K.
7.3.3.1 U.K. market estimates and forecast, 2014 - 2025
7.4 Asia Pacific
7.4.1 Asia Pacific market estimates and forecast, 2014 - 2025
7.4.2 Japan
7.4.2.1 Japan market estimates and forecast, 2014 - 2025
7.4.3 China
7.4.3.1 China market estimates and forecast, 2014 - 2025
7.5 Latin America
7.5.1 Brazil
7.5.1.1 Brazil market estimates and forecast, 2014 - 2025
7.5.2 Mexico
7.5.2.1 Mexico market estimates and forecast, 2014 - 2025
7.6 Middle East & Africa
7.6.1 Middle East And Africa market estimates and forecast, 2014 - 2025
7.6.2 Saudi Arabia
7.6.2.1 Saudi Arabia market estimates and forecast, 2014 - 2025
7.6.3 South Africa
7.6.3.1 South Africa market estimates and forecast, 2014 - 2025

Chapter 8 Company Profile
8.1 Abbott Laboratories
8.1.1 Company overview
8.1.2 Financial performance
8.1.3 Product benchmarking
8.1.4 Strategic initiatives
8.2 Roche Diagnostics
8.2.1 Company overview
8.2.2 Financial performance
8.2.3 Product benchmarking
8.2.4 Strategic initiatives
8.3 Qiagen
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Siemens Healthineers
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 Thermo Fischer Scientific Inc.
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Hologic
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 Becton, Dickinson and Company
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Sirtex Medical ltd.
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 Koninklijke Philips N.V.
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Illumina,Inc.
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abbott Laboratories
  • Roche Diagnostics
  • Qiagen
  • Siemens Healthineers
  • Thermo Fischer Scientific Inc.
  • Hologic
  • Becton, Dickinson and Company
  • Sirtex Medical ltd.
  • Koninklijke Philips N.V.
  • Illumina,Inc.
Note: Product cover images may vary from those shown
Adroll
adroll